Body of Evidence for Onasemnogene Abeparvovec in Spinal Muscular Atrophy Supports Long-Term Duration of Effect Without Relapse.

Value Health

Novartis Gene Therapies Switzerland GmbH, Rotkreuz, Switzerland. Electronic address:

Published: November 2022

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2021.10.019DOI Listing

Publication Analysis

Top Keywords

body evidence
4
evidence onasemnogene
4
onasemnogene abeparvovec
4
abeparvovec spinal
4
spinal muscular
4
muscular atrophy
4
atrophy supports
4
supports long-term
4
long-term duration
4
duration relapse
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!